EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A GLP‐1R/Y 1 receptor/Y 2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats

Antonia Caffrey, Enzo Lavecchia, Kylie S Chichura, Matthew R Hayes, Robert P Doyle, Heath D Schmidt iD

British Journal of Pharmacology · 2025-09 · 182 (18) · 4363-4379

DOI: 10.1111/bph.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 02.06.2025. Verfasst von Antonia Caffrey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Fentanyl, Nucleus Accumbens, Dopamine, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Emerging literature indicates that simultaneously targeting glucagon‐like peptide‐1 receptors (GLP‐1Rs) and neuropeptide Y receptors (Y 1 /Y 2 ) may represent a new pharmacotherapeutic approach to treating opioid use disorder (OUD). The overall goal of this study was to screen the efficacy of GEP12, a novel GLP‐1R/Y 1 receptor/Y 2 receptor triple agonist, to reduce voluntary fentanyl taking and seeking. Experimental Approach Rats were allowed to self‐administer fentanyl (2.5 μg kg −1 , i.v.) for 21 days. Rats were then pretreated with vehicle or GEP12 (1.57 or 12.53 μg kg −1 , i.p.) prior to fentanyl self‐administration test sessions. Opioid taking was then extinguished and rats were pretreated with vehicle or GEP12 (1.57 or 12.53 μg kg −1 , i.p.) prior to subsequent reinstatement test sessions. Key Results GEP12 reduced fentanyl taking in both male and female rats and shifted the fentanyl self‐administration dose–response curve downward. Importantly, we identified behaviourally selective doses of GEP12 that were well‐tolerated in fentanyl‐experienced rats. GEP12 also reduced fentanyl seeking during abstinence in both male and female rats at doses that did not alter food intake or produce adverse malaise‐like effects. To identify a central mechanism underlying the efficacy of GLP‐1R/Y 1 receptor/Y 2 receptor triple agonists, we showed that systemic GEP12 penetrated the brain and distributed to the mesolimbic reward system. Using in vivo fibre photometry, we discovered that GEP12 reduced fentanyl self‐administration‐evoked dopamine release in the nucleus accumbens. Conclusions and Implications Together, these findings support the continued development of GLP‐1R/Y 1 receptor/Y 2 receptor triple agonists as a novel class of pharmacotherapies for treating OUD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylNucleus AccumbensDopamineGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Neuropeptide YGlucagon-Like Peptide-1 ReceptorDrug-Seeking BehaviorAnalgesics, OpioidAnimalsMaleRatsRats, Sprague-DawleySelf AdministrationDose-Response Relationship, Drug

Stichwörter der Autor:innen

dopamineglucagon‐like peptide‐1neuropeptide Ynucleus accumbensopioidrelapse

Substanzen

FentanylDopamineGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Neuropeptide Yneuropeptide Y2 receptorGlucagon-Like Peptide-1 ReceptorAnalgesics, OpioidGlp1r protein, rat

Autor:innen und Institutionen

  • Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Chemistry, Syracuse University, Syracuse, New York, USA.
  • Departments of Medicine and Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York, USA.

ORCID-Profile: Heath D Schmidt

Förderung

  • U.S. Department of Defense
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Caffrey, A., Lavecchia, E., Chichura, K. S., Hayes, M. R., Doyle, R. P., & Schmidt, H. D. (2025). A GLP‐1R/Y 1 receptor/Y 2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats. British Journal of Pharmacology, 182(18), 4363-4379. https://doi.org/10.1111/bph.70096

Vancouver

Caffrey A, Lavecchia E, Chichura KS, Hayes MR, Doyle RP, Schmidt HD. A GLP‐1R/Y 1 receptor/Y 2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats. British Journal of Pharmacology. 2025;182(18):4363-4379. doi:10.1111/bph.70096

BibTeX
@article{Caffrey2025,
  author = {Caffrey, Antonia and Lavecchia, Enzo and Chichura, Kylie S and Hayes, Matthew R and Doyle, Robert P and Schmidt, Heath D},
  title = {A GLP‐1R/Y 1 receptor/Y 2 receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {18},
  pages = {4363--4379},
  doi = {10.1111/bph.70096}
}
Kostenlos starten →